Early-Onset Hypertrophic Cardiomyopathy Mutations Significantly Increase the Velocity, Force, and Actin-Activated ATPase Activity of Human β-Cardiac Myosin-Reference-Cited by-同舟云学术

Early-Onset Hypertrophic Cardiomyopathy Mutations Significantly Increase the Velocity, Force, and Actin-Activated ATPase Activity of Human β-Cardiac Myosin

Published:2016-12 Issue:11 Volume:17 Page:2857-2864
ISSN:2211-1247
Container-title:Cell Reports
language:en
Short-container-title:Cell Reports

Author:

Adhikari Arjun S.,Kooiker Kristina B.,Sarkar Saswata S.,Liu Chao,Bernstein Daniel,Spudich James A.,Ruppel Kathleen M.

Funder

NIH

Lucile Packard CHRI

Stanford ChEM-H Postdocs at the Interface

Stanford CVI Postdoctoral

American Heart Association

NIH T32 Training Grant in Myocardial Biology

Stanford Spectrum Translational Medicine

NIGMS

Stanford Bio-X

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference45 articles.

1. Ensemble force changes that result from human cardiac myosin mutations and a small-molecule effector;Aksel;Cell Rep.,2015

2. Atomic model of the human cardiac muscle myosin filament;Al-Khayat;Proc. Natl. Acad. Sci. USA,2013

3. Three-dimensional reconstruction of tarantula myosin filaments suggests how phosphorylation may regulate myosin activity;Alamo;J. Mol. Biol.,2008

4. Molecular and phenotypic effects of heterozygous, homozygous, and compound heterozygote myosin heavy-chain mutations;Alpert;Am. J. Physiol. Heart Circ. Physiol.,2005

5. Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry;Colan;Circulation,2007

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reassessing the unifying hypothesis for hypercontractility caused by myosin mutations in hypertrophic cardiomyopathy;The EMBO Journal;2024-08-27

2. Phenotypic Spectrum of Subclinical Sarcomere-Related Hypertrophic Cardiomyopathy and Transition to Overt Disease;Circulation: Genomic and Precision Medicine;2024-08

3. Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy;Nature Cardiovascular Research;2024-07-23

4. YAP dysregulation triggers hypertrophy by CCN2 secretion and TGFβ uptake in human pluripotent stem cell-derived cardiomyocytes;2024-06-03

5. Target population for a selective cardiac myosin inhibitor in hypertrophic obstructive cardiomyopathy: Real-life estimation from the French register of hypertrophic cardiomyopathy (REMY);Archives of Cardiovascular Diseases;2024-06